UK markets close in 8 hours 22 minutes

BNTX Dec 2025 150.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
57.610.00 (0.00%)
As of 10:50AM EDT. Market open.
Full screen
Previous close57.61
Open59.50
Bid55.90
Ask60.20
Strike150.00
Expiry date2025-12-19
Day's range57.61 - 57.61
Contract rangeN/A
Volume3
Open interest4
  • Globe Newswire

    BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

    MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi

  • Thomson Reuters StreetEvents

    Q1 2024 Autolus Therapeutics PLC Earnings Call

    Q1 2024 Autolus Therapeutics PLC Earnings Call

  • Benzinga

    European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

    Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte